To investigate how urogenital infections influence the discontinuation rate of SGLT2i medications in patients with Type 2 diabetes.
Conducted a matched cohort study using population-based data.
Included patients with Type 2 diabetes who initiated SGLT2i.
Analyzed the incidence of SGLT2i discontinuation following UTIs and GTIs.
Patients experiencing a UTI or GTI had higher rates of SGLT2i discontinuation.
The elevated frequency indicates a significant association between infections and treatment discontinuation.
Abstract
Patients with Type 2 diabetes who initiate SGLT2i and experience a UTI or GTI within the following year have an elevated frequency of subsequent SGLT2i discontinuation.